Navigation Links
Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
Date:3/2/2009

SAN DIEGO, March 2 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) today announced that Patrick Mahaffy has been appointed to the Company's Board of Directors to fill an existing vacancy on the board.

Mr. Mahaffy brings significant biotechnology and pharmaceutical executive management experience. He was the founder of Pharmion Corporation and served as its President and CEO from its inception through its acquisition eight years later. Under Mr. Mahaffy's leadership, Pharmion successfully acquired, developed and gained approval for several oncology products in the U.S. and Europe and achieved significant revenues and sustained growth from those products until its acquisition by Celgene Corporation for $2.9 billion in March 2008. Mr. Mahaffy is presently creating a new company dedicated to acquiring and developing oncology drug products.

"Patrick has a proven track record in successfully managing all facets of drug development and commercialization, and his experience will be incredibly valuable as we complete the Phase 3 program for Contrave, our lead obesity product candidate," said Eckard Weber, M.D., Executive Chairman and Interim President and CEO. "In addition, his knowledge and experience in strategic business development will be important as we continue to explore partnership opportunities and execute on broader business strategies."

Prior to co-founding Pharmion, Mr. Mahaffy was President and CEO of NeXagen, Inc. and its successor, NeXstar Pharmaceuticals Inc. from 1992 until 1999. He is credited for developing corporate partnerships with Eli Lilly and Co., Systemix/Sandoz, Schering AG and Becton, Dickinson and Co. He took NeXstar Pharmaceuticals public in 1994 and in 1995 acquired publicly-traded company Vestar. In July 1999, Gilead acquired NeXstar Pharmaceuticals for $800 million. Mr. Mahaffy received a B.A. from Lewis and Clark College and an M.A. from Columbia School of International Affairs.

About Orexigen(R) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
2. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
3. Prime Therapeutics Receives TIPPS Certification
4. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
5. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
6. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
7. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
8. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
9. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
10. Prime Therapeutics Announces URAC Accreditation
11. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Regular gym ... find themselves having to wait longer to access the treadmills. It’s a predictable trend. ... resolutions to lose weight and get in shape by joining gyms, starting new walking ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... in need. The event is scheduled to take place on February 27, 2016 from ... dental care to community members in need. Each patient will be given the opportunity ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a ... individuals in the event they are experiencing an illness. Migraines are a severe form ... are afflicted with migraines would not wish the pain on their worst enemy, the ...
(Date:2/5/2016)... ... 2016 , ... –This week, Atascadero water heater company First Call Plumbing ... To view the report, click here or see below. , There ... pros and cons, the type chosen is almost entirely up to personal preference. However, ...
(Date:2/4/2016)... ... February 04, 2016 , ... American Addiction Centers ... the start of Project HoldSpace. Through the partnership, the two organizations seek to ... youth between the ages of 13 and 18. Currently focused on Ohio schools, ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Patients in Alabama seeking ... therapy no longer have to travel out of state. ... Urology Centers of Alabama to provide a total ... qualifying patients. Alabama is ... of prostate cancer using many different modalities. They are the ...
(Date:2/5/2016)... 2016 --> ... that the global active pharmaceuticals ingredients (APIs) market stood ... reach US$185.9 bn by 2020. It is expected to ... 2020. The title of the report is "Active Pharmaceutical ... and by Therapeutic Area) - Global Industry Analysis, Size, ...
(Date:2/5/2016)... 2016 Site Profile: --> ... - The Speech Recognition People, announced their latest primary healthcare case ... care, reduce turnaround times and to save the practice money. ... since 2013 Challenge: --> ,- Wirral CCG ... - Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
Breaking Medicine Technology: